The population of CD20+ B cells/mm2 of the parenchyma at baseline, i.e., the histopathological profiles of a parotid biopsy, may potently affect the efficacy of RTX in patients with pSS (Delli et al., 2016). Here, MS4A1 is linked to peeling skin syndrome.